Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ODI-2001 (Centre Georges-François Leclerc)
- Development stage
- Unknown
- Lead developer
- Odimma Therapeutics
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular, Intravenous
01
Overview
ODI-2001 is a personalized therapeutic cancer vaccine regimen being developed by Centre Georges Francois Leclerc. It consists of a combination of a DNA neoantigen vaccine, a Modified Vaccinia virus Ankara (MVA) viral vector adjuvant, and the checkpoint inhibitor ipilimumab (an anti-CTLA-4 monoclonal antibody). The vaccine is designed to stimulate a patient-specific immune response against tumor-specific neoantigens. The DNA vaccine provides the genetic template for the neoantigens, while the MVA vector acts as a potent viral adjuvant to enhance the immune response. Ipilimumab works by blocking the CTLA-4 checkpoint, thereby sustaining T-cell activation and overcoming tumor-induced immunosuppression. It is currently being evaluated in Phase 1 trials for metastatic or locally advanced colorectal and pancreatic cancers.
- Other names
- personalized cancer vaccine + ipilimumabDNA neoantigen vaccine + MVA + ipilimumab
02
Targets
Neoepitope-MHC-I (Patient-specific neoepitope-Major Histocompatibility Complex class I complex)pMHC-II (Peptide-major histocompatibility complex class II complex)T-cell receptor specific for ODI-2001 neoepitope–MHC complexCTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on ODI-2001 (Centre Georges-François Leclerc).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ODI-2001 (Centre Georges-François Leclerc).